Overview

Seqens is an integrated billion-dollar global leader in pharmaceutical synthesis and specialty ingredients. Seqens CDMO North America (formerly known as PCI Synthesis, Inc.), a division of Seqens, is a Contract Development and Manufacturing Organization (CDMO) that provides biotech and pharmaceutical companies with the expertise and capacity needed to develop and manufacture complex small molecules including active pharmaceutical ingredients (APIs), intermediates and other specialty products, whether at research, development or commercial scale. The company also has extensive expertise in medical-grade polymer synthesis, flow chemistry, biocatalysis and highly potent APIs. Seqens offers tailor-made solutions to sponsors for all their API needs.

Based in Newburyport, Mass., Seqens CDMO NA operates a cGMP facility in Massachusetts, where its R&D and kilo labs are fully integrated with commercial manufacturing capabilities of up to 2000 gallons. The company is able to offer unique local presence, but global resources across the company’s 7 R&D centers and 24 manufacturing sites in Europe, North America and Asia.

Company News

News

Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston

Feb 09, 2023

Posted by SEQENS CDMO NA

News

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory (Devens, MA)

Mar 31, 2022

Posted by SEQENS CDMO NA

See all Members